Table 6 Indirect comparison results: duloxetine vs. gabapentin.
Outcome | Indirect treatment comparison (δ) Mean (median) | 95% CI for δ | Between-study variance (τ 2) Mean (median) | 95% CI for τ 2 |
|---|---|---|---|---|
Efficacy | ||||
Reduction in 24-hour pain intensity | 0.270 (0.266) | (-0.469; 1.022) | 0.041 (0.013) | (0.001; 0.247) |
Tolerability | ||||
Premature study discontinuation due to: | ||||
- Lack of efficacy | 0.067 (0.065) | (-1.988; 2.116) | 0.177 (0.028) | (0.001; 1.281) |
- Adverse events | 0.841 (0.835) | (-0.348; 2.065) | 0.062 (0.015) | (0.001; 0.406) |
- Other | -0.245 (-0.252) | (-1.527; 1.075) | 0.060 (0.015) | (0.001; 0.386) |
Diarrhoea | -0.244 (-0.246) | (-1.645; 1.164) | 0.273 (0.051) | (0.001; 1.825) |
Dizziness | -1.044 (-1.054) | (-2.258; 0.183) | 0.090 (0.021) | (0.001; 0.590) |
Headache | -0.689 (-0.697) | (-1.986; 0.638) | 0.053 (0.013) | (0.001; 0.348) |
Nausea | 0.704 (0.700) | (-0.567; 2.021) | 0.085 (0.022) | (0.001; 0.529) |
Somnolence | -0.101 (-0.107) | (-1.249; 1.078) | 0.080 (0.016) | (0.001; 0.545) |